特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
949492

世界の筋弛緩剤市場:2020年~2026年

Global Muscle Relaxant Drug Market 2020-2026

出版日: | 発行: Orion Market Research Pvt Ltd | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.70円
世界の筋弛緩剤市場:2020年~2026年
出版日: 2020年06月01日
発行: Orion Market Research Pvt Ltd
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の筋弛緩剤市場は予測期間中に大幅に成長すると予測されています。 世界の筋弛緩剤市場の成長を牽引している主な要因には、筋骨格系障害にかかりやすい高齢者の数の増加があり、それが筋弛緩剤の採用を高め、それにより予測期間中の市場の成長を促進しています。さらに、薬物の入手可能性に伴う人々の疼痛症状の罹患率の上昇は、予測期間中の市場の成長を推進しています。ただし、同薬剤に関連するいくつかの副作用は、市場の成長を妨げる可能性があります。

世界の筋弛緩剤市場は、 製品タイプと製剤に基づいて分割されます。 製品タイプ別では、世界の筋弛緩剤市場は、末梢性筋弛緩剤、フェイシャルエステ用弛緩剤、および中枢性筋弛緩剤に分類されます。末梢性筋弛緩剤セグメントは、予測期間にわたって市場で大きなシェアを保持しています。製剤別では、市場は経口剤と注射剤に分かれています。経口セグメントは、市場で最も重要なシェアを保持する可能性があります。

地理的に、 世界の筋弛緩剤市場レポートは、 北米 (米国およびカナダ)、欧州(英国、ドイツ、イタリア、スペイン、フランス、 その他)、アジア太平洋地域(中国、日本、インド、その他)、その他の諸国の4つの主要地域を網羅しています。アジア太平洋地域は、予測期間中に世界の筋弛緩剤市場で大きな成長率を示すと推定されています。この地域での老齢人口の増加は、市場の成長を牽引しています。さらに、 ヘルスケアインフラの改善は、市場の地域的な成長をさらに後押しします。

当レポートでは、世界の筋弛緩剤市場について調査し、市場の概要とともに、製品タイプ別、製剤別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
  • 規則と規制

第3章 競合情勢

  • 主要戦略分析
  • 主要企業分析
    • 概観
    • 財務分析
    • SWOT分析
    • 最近の進展

第4章 市場決定要因

  • 動機
  • 抑制要因
  • 市場機会

第5章 市場セグメンテーション

  • 製品タイプ別世界の筋弛緩剤市場
    • 末梢性筋弛緩剤
    • フェイシャルエステ用弛緩剤
    • 中枢性筋弛緩剤
  • 製剤別世界の筋弛緩剤市場
    • 経口剤
    • 注射剤

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • その他アジア太平洋
  • その他の地域

第7章 企業プロファイル

  • AbbVie Inc.
  • Acorda Therapeutics Inc.
  • Aurobindo Pharma Ltd.
  • Cadila Healthcare Ltd.
  • DBL Pharma Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Endo Pharmaceuticals Inc.
  • Ipsen Biopharmaceuticals Inc.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Mylan NV
  • Neurana Pharmaceuticals
  • Novartis International AG
  • Orient Pharma Co. Ltd.
  • Par Pharmaceutical Inc.
  • Pfizer Inc.
  • Vertical Pharmaceuticals LLC
図表

LIST OF TABLES

  • 1. GLOBAL MUSCLE RELAXANT DRUG MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)
  • 2. GLOBAL PERIPHERALLY ACTING MUSCLE RELAXANTS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL FACIAL AESTHETIC RELAXANTS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL CENTRALLY ACTING MUSCLE RELAXANTS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL MUSCLE RELAXANT DRUG MARKET RESEARCH AND ANALYSIS BY FORMULATION, 2019-2026 ($ MILLION)
  • 6. GLOBAL ORAL MUSCLE RELAXANT DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL INJECTABLE MUSCLE RELAXANT DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 8. GLOBAL MUSCLE RELAXANT DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 9. NORTH AMERICAN MUSCLE RELAXANT DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 10. NORTH AMERICAN MUSCLE RELAXANT DRUG MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)
  • 11. NORTH AMERICAN MUSCLE RELAXANT DRUG MARKET RESEARCH AND ANALYSIS BY FORMULATION, 2019-2026 ($ MILLION)
  • 12. EUROPEAN MUSCLE RELAXANT DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 13. EUROPEAN MUSCLE RELAXANT DRUG MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)
  • 14. EUROPEAN MUSCLE RELAXANT DRUG MARKET RESEARCH AND ANALYSIS BY FORMULATION, 2019-2026 ($ MILLION)
  • 15. ASIA-PACIFIC MUSCLE RELAXANT DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 16. ASIA-PACIFIC MUSCLE RELAXANT DRUG MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)
  • 17. ASIA-PACIFIC MUSCLE RELAXANT DRUG MARKET RESEARCH AND ANALYSIS BY FORMULATION, 2019-2026 ($ MILLION)
  • 18. REST OF THE WORLD MUSCLE RELAXANT DRUG MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)
  • 19. REST OF THE WORLD MUSCLE RELAXANT DRUG MARKET RESEARCH AND ANALYSIS BY FORMULATION, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL MUSCLE RELAXANT DRUG MARKET SHARE BY PRODUCT TYPE, 2019 VS 2026 (%)
  • 2. GLOBAL MUSCLE RELAXANT DRUG MARKET SHARE BY FORMULATION, 2019 VS 2026 (%)
  • 3. GLOBAL MUSCLE RELAXANT DRUG MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 4. US MUSCLE RELAXANT DRUG MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. CANADA MUSCLE RELAXANT DRUG MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. UK MUSCLE RELAXANT DRUG MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. FRANCE MUSCLE RELAXANT DRUG MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. GERMANY MUSCLE RELAXANT DRUG MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. ITALY MUSCLE RELAXANT DRUG MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. SPAIN MUSCLE RELAXANT DRUG MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. ROE MUSCLE RELAXANT DRUG MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. INDIA MUSCLE RELAXANT DRUG MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. CHINA MUSCLE RELAXANT DRUG MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. JAPAN MUSCLE RELAXANT DRUG MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC MUSCLE RELAXANT DRUG MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF THE WORLD MUSCLE RELAXANT DRUG MARKET SIZE, 2019-2026 ($ MILLION)
目次
Product Code: OMR2021811

Global Muscle Relaxant Drug Market Size, Share & Trends Analysis Report by Product Type (Peripherally Acting Muscle Relaxants, Facial Aesthetic Relaxants, and Centrally Acting Muscle Relaxants), By Formulation (Oral and Injectable) Forecast, 2020-2026

The global muscle relaxant drug market is projected to grow significantly during the forecast period. The primary factors that are driving the growth of the global muscle relaxant drug industry include the increased number of geriatric populations who are more prone to musculoskeletal disorders which in turn enhances the adoption of muscle relaxant drugs and thereby fuel the market growth during the forecast period. Further, the rising prevalence of pain conditions in the peoples along with the availability of drugs is propelling the growth of the market during the forecast period. However, some side effects associated with the drugs may challenge the growth of the market.

The global muscle relaxant drug market is segmented on the basis of product type and formulation. Based on the product type, the global muscle relaxant drug industry is segmented into peripherally acting muscle relaxants, facial aesthetic relaxants, and centrally acting muscle relaxants. Peripherally acting muscle relaxants segment holds a significant share in the market over the forecast period. Based on the formulation, the market is bifurcated into oral and injectable. The oral segment is likely to hold the most significant share in the market.

Geographically, the study of the global muscle relaxant drug market report covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), and the Rest of the World. Asia-Pacific is estimated to exhibit a significant growth rate in the global muscle relaxant drug market during the forecast period. The increasing geriatric population in the region drives the growth of the market. In addition, improving healthcare infrastructure further gives a boost to the regional growth of the market.

Further, AbbVie Inc., Acorda Therapeutics Inc., Cadila Healthcare Ltd., Dr. Reddy's Laboratories Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Mylan NV, Orient Pharma Co. Ltd., Par Pharmaceutical Inc., and Pfizer Inc. are some of the prominent players operating in the global muscle relaxant drug market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players to sustain in the highly competitive market.

Research Methodology

The market study of the global muscle relaxant drug market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary sources include:

  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog

The report is intended for muscle relaxant drug market players, drug manufacturing companies, investment companies, industry associations & experts, research institutes, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:

1. Global Muscle Relaxant Drug Market Research and Analysis by Type

2. Global Muscle Relaxant Drug Market Research and Analysis by Route of Administration

The Report Covers:

  • Comprehensive research methodology of the global muscle relaxant drug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global muscle relaxant drug market.
  • Insights about market determinants which are stimulating the global muscle relaxant drug market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of the market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Key Strategy Analysis
  • 3.2. Key Company Analysis
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Muscle Relaxant Drug Market by Product Type
    • 5.1.1. Peripherally Acting Muscle Relaxants
    • 5.1.2. Facial Aesthetic Relaxants
    • 5.1.3. Centrally Acting Muscle Relaxants
  • 5.2. Global Muscle Relaxant Drug Market by Formulation
    • 5.2.1. Oral
    • 5.2.2. Injectable

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. AbbVie Inc.
  • 7.2. Acorda Therapeutics Inc.
  • 7.3. Aurobindo Pharma Ltd.
  • 7.4. Cadila Healthcare Ltd.
  • 7.5. DBL Pharma Inc.
  • 7.6. Dr. Reddy's Laboratories Ltd.
  • 7.7. Endo Pharmaceuticals Inc.
  • 7.8. Ipsen Biopharmaceuticals Inc.
  • 7.9. Johnson & Johnson Services Inc.
  • 7.10. Merck & Co. Inc.
  • 7.11. Mylan NV
  • 7.12. Neurana Pharmaceuticals
  • 7.13. Novartis International AG
  • 7.14. Orient Pharma Co. Ltd.
  • 7.15. Par Pharmaceutical Inc.
  • 7.16. Pfizer Inc.
  • 7.17. Vertical Pharmaceuticals LLC
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.